drugset
drugset / Trial / NCT07226726

Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution

NCT07226726 ↗

Phase 1 Recruiting 20 enrolled The Foundation for Orthopaedics and Regenerative Medicine
NaSingle-groupOpen-labelTreatment

Summary

Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.

Timeline

Start
2025-01-01
Primary completion
2028-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject AlloEx exosomes Other / unclassified — Intranasal

Indications

congenital myasthenic syndrome